Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Guselkumab brand name?
Dabrafenib patent expiration date novartis gsk composition matter?
Pramlintide approval date?
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
Norcuron generic name?

Does latisse expire?

See the DrugPatentWatch profile for latisse

Does Latisse (bimatoprost) “expire” as a product name?

Latisse is the brand name for prescription bimatoprost solution used to treat hypotrichosis (inadequate eyelashes). Brand drug protection doesn’t behave like a simple “expiration date” for the product itself; what matters is when exclusivity and patents end, which can allow cheaper generic or authorized versions to enter.

When does Latisse exclusivity/patent protection end?

DrugPatentWatch.com tracks patent and exclusivity status for branded drugs, including how long manufacturers retain market exclusivity before generic competition can launch. You can check the latest status for Latisse here: DrugPatentWatch – Latisse

Is there an expiration date on the physical Latisse bottle?

If you mean shelf-life rather than legal exclusivity: every medication bottle has an expiration date set by the manufacturer, and you should not use the product after that date. (This is separate from patent/exclusivity timelines.)

How to tell which “expiration” you’re asking about

If you’re deciding whether you can switch to a cheaper option, the relevant question is patent/exclusivity (timelines vary by country and specific protections). If you’re deciding whether your bottle is still usable, the relevant question is the printed expiration date and storage instructions on your medication.

Quick check: which country matters?

Patent and exclusivity rules differ by country, so tell me where you are (US, UK, Canada, etc.) and whether you mean legal availability or the shelf-life date on the bottle.

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided claims include general statements about brand protection, patents/exclusivity, and medication expiration dates that are not prescribing-information content. Only a subset of claims (drug name/indication) appears to be supportable by the provided LATISSE (bimatoprost 0.03%) labeling excerpts; the remaining claims cannot be reliably matched to the provided labeling sections.

Alignment Scorecard

Category	Status	Notes
Indication	Aligned	“Hypotrichosis (inadequate eyelashes)” aligns with indication to treat hypotrichosis of the eyelashes and increase growth.
Patient Population	Unable to Assess	No patient population specifics were included in the claims; the label excerpts provided do not include population boundaries relevant to the given statements.
Dosage & Administration	Unable to Assess	No dosing/administration claims were provided in the list.
Contraindications	Unable to Assess	No contraindication-related claims were provided.
Warnings & Precautions	Unable to Assess	No warning-specific claims were provided in the list (e.g., lid pigmentation, hair growth outside area, IOP context).
Drug Interactions	Unable to Assess	No drug interaction claims were provided.
Adverse Reactions	Unable to Assess	No adverse reaction claims were provided.
Monitoring	Not Applicable	Monitoring statements were not included in the provided claims.
Administration Instructions	Unable to Assess	No administration-instruction claims were provided.
Limitations of Use	Unable to Assess	No limitations-of-use claims were provided.
Special Populations	Unable to Assess	No pregnancy/pediatrics/renal/hepatic claims were provided.

Key Findings

Claim about LATISSE being bimatoprost ophthalmic solution is consistent with labeling.
The indication claim (hypotrichosis of eyelashes) is supported by the provided “Indications and Usage” excerpt.
Statements about “brand drug protection,” patents/exclusivity, country differences, and expiration-date/patent timelines are not prescribing-information topics in the provided LATISSE excerpts and cannot be verified against them.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Latisse is the brand name for prescription bimatoprost solution.	Supported	Provided labeling identifies LATISSE as bimatoprost ophthalmic solution 0.03%.	Informational
Bimatoprost (Latisse) solution is used to treat hypotrichosis (inadequate eyelashes).	Supported	“Indications and Usage”: treat hypotrichosis of the eyelashes by increasing growth (length, thickness, darkness).	Moderate
Brand drug protection does not behave like a simple expiration date for the product itself.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational
What matters for brand protection is when exclusivity and patents end.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational
When exclusivity and patents end, cheaper generic or authorized versions can enter.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational
Every medication bottle has an expiration date set by the manufacturer.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational
You should not use the product after its printed expiration date.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	High
Shelf-life expiration and patent/exclusivity timelines are separate.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational
Patent and exclusivity rules differ by country.	Cannot Determine	Not addressed in the provided LATISSE prescribing-information excerpts.	Informational

Important Omissions

Prescribing-information-aligned content is largely absent for key clinical sections (dosage/administration, contraindications, warnings/precautions, adverse reactions, and special populations) because the provided claims focus on non-prescribing topics.

Unsupported / Hallucinated Content

None identified as contradicted by the provided LATISSE prescribing-information excerpts.
Several claims cannot be verified against the provided labeling excerpts (included above as “Cannot Determine”).

Potential Patient Safety Concerns

At least one claim could be patient-relevant (“You should not use the product after its printed expiration date”), but it cannot be confirmed from the provided LATISSE prescribing-information excerpts. No other clinically safety claims were provided in the list.

Overall Assessment

The two clinically oriented claims (brand-to-active ingredient identification and the indicated condition of hypotrichosis of the eyelashes with increased lash growth) are aligned with the provided LATISSE labeling excerpts. The remaining claims concern patent/exclusivity and expiration-timeline concepts that are not included in the supplied prescribing-information sections, so labeling adherence cannot be established for them.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

prescription bimatoprost solution used to treat hypotrichosis (inadequate eyelashes)

Core Claims

Latisse is the brand name for prescription bimatoprost solution used to treat hypotrichosis (inadequate eyelashes).
Brand drug protection doesn’t behave like a simple “expiration date” for the product itself.
What matters is when exclusivity and patents end.
Every medication bottle has an expiration date set by the manufacturer, and you should not use the product after that date.
Patent/exclusivity and shelf-life are separate.

Differentiators

Explains the distinction between legal exclusivity/patents and the bottle’s shelf-life expiration date.
Points to checking patent/exclusivity status to understand generic/authorized versions.

Pricing Perception: Not Mentioned